Show simple item record

AuthorIbrahim, AlZaim
AuthorEid, Ali H.
AuthorAbd-Elrahman, Khaled S.
AuthorEl-Yazbi, Ahmed F.
Available date2023-03-05T09:34:23Z
Publication Date2022-12-31
Publication NameBiochemical Pharmacology
Identifierhttp://dx.doi.org/10.1016/j.bcp.2022.115337
CitationAlZaim I, Eid AH, Abd-Elrahman KS, El-Yazbi AF. Adipose tissue mitochondrial dysfunction and cardiometabolic diseases: On the search for novel molecular targets. Biochem Pharmacol. 2022 Dec;206:115337. doi: 10.1016/j.bcp.2022.115337.
ISSN00062952
URIhttps://www.sciencedirect.com/science/article/pii/S0006295222004312
URIhttp://hdl.handle.net/10576/40654
AbstractCardiometabolic diseases present an escalating global health and economic burden. Such a surge is driven by epidemic prevalence rates of metabolic disorders, such as obesity and type 2 diabetes, and their associated cardiovascular complications, majorly contributing to morbidity and mortality. A fundamental challenge impeding the effective management and therapy of these complications is a lack of clear understanding of the molecular mechanisms underpinning disease initiation and progression. Over the past decade, a role for metabolic disease-associated adipose tissue dysfunction and inflammation in evoking cardiovascular and renal deterioration emerged, together with a growing recognition of the positive impact of pharmacological tools modulating adipose tissue function. Adipose tissue is a plastic endocrine organ whose homeostasis is essentially dependent on the intercellular communication of its comprising cellular components. Yet, despite being a principal regulator of adipose tissue metabolic activity, changes in aspects of adipose tissue mitochondrial biogenesis, dynamics, and bioenergetics in the context of cardiometabolic disorders have not garnered the necessary attention. Here, we gather the available evidence on the contribution of mitochondrial dysfunction to that of the adipose tissue in metabolic diseases, and to the ensuing cardiovascular deterioration. The involved molecular pathways are highlighted together with potential targets for intervention. The effects of several drug classes with known beneficial impact on adipose tissue remodeling and mitochondrial dysfunction in such a context are discussed. Finally, future research aspects in this domain are explored.
SponsorThis work is supported by a grant #45912 from the Science, Technology, and Innovation Funding Authority in Egypt to AFE.
Languageen
PublisherElsevier
SubjectMetabolic disease
Cardiovascular disease
Mitochondria
Adipose
UCP1
TitleAdipose tissue mitochondrial dysfunction and cardiometabolic diseases: On the search for novel molecular targets
TypeArticle
Volume Number206
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record